SCHEMBL20133945

SCHEMBL20133945

NNc1ccc(C(=O)ON2C(=O)CCC2=O)cc1

nearest known ligand 0.43

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.43
HPGD P15428 2/20 0.43
KMT2A Q03164 5/20 0.41
MEN1 O00255 3/20 0.41
MGLL Q99685 2/20 0.36
MAPT P10636 3/20 0.35
CA12 O43570 1/20 0.34
CA1 P00915 1/20 0.34
CA9 Q16790 1/20 0.34
SMN1; SMN2 Q16637 3/20 0.33
KDM4E B2RXH2 1/20 0.33
GAA P10253 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7910402 0.98 ALDH1A1 (0.43) ALDH1A1HPGDKMT2AMEN1MGLL
Hydrochloric Acid SCHEMBL7910504 0.98 ALDH1A1 (0.43) ALDH1A1HPGDKMT2AMEN1MGLL
SCHEMBL300884 0.86 CA12 (0.42) ALDH1A1HPGDKMT2AMEN1MGLL
SCHEMBL10168511 0.84 ALDH1A1 (0.47) ALDH1A1HPGDKMT2AMEN1MAPT
SCHEMBL28320394 0.84 ALDH1A1 (0.38) ALDH1A1HPGDKMT2AMEN1MGLL
SCHEMBL16938405 0.84 MAPT (0.54) ALDH1A1HPGDKMT2AMEN1MAPT
Hydrochloric Acid SCHEMBL28721885 0.83 ALDH1A1 (0.37) ALDH1A1HPGDKMT2AMEN1MGLL
Hydrochloric Acid SCHEMBL29064019 0.83 MAPT (0.53) ALDH1A1HPGDKMT2AMEN1MGLL
SCHEMBL7327634 0.82 HPGD (0.46) ALDH1A1HPGDKMT2AMEN1MAPT
SCHEMBL12216547 0.81 LMNA (0.44) ALDH1A1HPGDKMT2AMAPTCA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114040760-B Irreversible inhibitors of MENIN-MLL interactions 拜欧米富士恩公司 2025-05-09 CN disclosed
CN-119841834-A Irreversible inhibitors of MENIN-MLL interactions 拜欧米富士恩公司 2025-04-18 CN disclosed
US-20250020674-A1 CHOLESTEROL-RICH LIPOPROTEIN NANOPARTICLES FOR CANCER DIAGNOSIS ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) 2025-01-16 US disclosed
CN-113195471-B Polysubstituted pyridone derivative and application thereof in medicine 苏州浦合医药科技有限公司 2023-05-02 CN disclosed
US-10414826-B2 Monomethylvaline compounds capable of conjugation to ligands SEATTLE GENETICS, INC. (US) 2019-09-17 US disclosed
US-20180127512-A1 MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS SEAGEN INC. 2018-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180127512-A1 MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS MMAB, CAD, VIM ALDH1A1 3456/4885HPGD 2535/4885KMT2A 2858/4885
US-10414826-B2 Monomethylvaline compounds capable of conjugation to ligands MMAB, CAD, VIM ALDH1A1 3456/4885HPGD 2535/4885KMT2A 2858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.